Effect of magnesium oxide or citrate supplements on metabolic risk factors in kidney stone formers with idiopathic hyperoxaluria: a randomized clinical trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Magnesium is one of the recommended treatments for calcium stone formers (CSFs) with hyperoxaluria.

In this study, the researchers compared the effect of magnesium oxide (MgO) or magnesium citrate (MgCit) with placebo on 24-hour urine (24-U) metabolites and the calcium oxalate supersaturation index (CaOx SS).

Who Took Part

The abstract describes 76 patients taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Finally, 76 patients were included in the final analysis.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

Study outcomes included changes in 24-U oxalate, magnesium, citrate, and CaOx SS.

The subject headings attached to it are Magnesium Oxide, Kidney Calculi, Dietary Supplements, Hyperoxaluria, Risk Factors, Citric Acid and Magnesium Compounds.

Author keywords: calcium oxalate, kidney stone and magnesium citrate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 76 patients.

The publication is from 2024 (Magnesium research), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.